225 related articles for article (PubMed ID: 22283559)
1. Randomized open-label drug-drug interaction trial of dextromethorphan/quinidine and paroxetine in healthy volunteers.
Schoedel KA; Pope LE; Sellers EM
Clin Drug Investig; 2012 Mar; 32(3):157-69. PubMed ID: 22283559
[TBL] [Abstract][Full Text] [Related]
2. A study of potential pharmacokinetic and pharmacodynamic interactions between dextromethorphan/quinidine and memantine in healthy volunteers.
Pope LE; Schoedel KA; Bartlett C; Sellers EM
Clin Drug Investig; 2012 Aug; 32(8):e1-15. PubMed ID: 22712629
[TBL] [Abstract][Full Text] [Related]
3. An open-label multicenter study to assess the safety of dextromethorphan/quinidine in patients with pseudobulbar affect associated with a range of underlying neurological conditions.
Pattee GL; Wymer JP; Lomen-Hoerth C; Appel SH; Formella AE; Pope LE
Curr Med Res Opin; 2014 Nov; 30(11):2255-65. PubMed ID: 25062507
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of dextromethorphan after single or multiple dosing in combination with quinidine in extensive and poor metabolizers.
Pope LE; Khalil MH; Berg JE; Stiles M; Yakatan GJ; Sellers EM
J Clin Pharmacol; 2004 Oct; 44(10):1132-42. PubMed ID: 15342614
[TBL] [Abstract][Full Text] [Related]
5. Safety, Tolerability, and Effectiveness of Dextromethorphan/Quinidine for Pseudobulbar Affect Among Study Participants With Traumatic Brain Injury: Results From the PRISM-II Open Label Study.
Hammond FM; Sauve W; Ledon F; Davis C; Formella AE
PM R; 2018 Oct; 10(10):993-1003. PubMed ID: 29477412
[TBL] [Abstract][Full Text] [Related]
6. AVP-923, a combination of dextromethorphan hydrobromide and quinidine sulfate for the treatment of pseudobulbar affect and neuropathic pain.
Olney N; Rosen H
IDrugs; 2010 Apr; 13(4):254-65. PubMed ID: 20373255
[TBL] [Abstract][Full Text] [Related]
7. PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury.
Hammond FM; Alexander DN; Cutler AJ; D'Amico S; Doody RS; Sauve W; Zorowitz RD; Davis CS; Shin P; Ledon F; Yonan C; Formella AE; Siffert J
BMC Neurol; 2016 Jun; 16():89. PubMed ID: 27276999
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of dextromethorphan/quinidine at two dosage levels for diabetic neuropathic pain: a double-blind, placebo-controlled, multicenter study.
Shaibani AI; Pope LE; Thisted R; Hepner A
Pain Med; 2012 Feb; 13(2):243-54. PubMed ID: 22314263
[TBL] [Abstract][Full Text] [Related]
9. Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial.
Brooks BR; Thisted RA; Appel SH; Bradley WG; Olney RK; Berg JE; Pope LE; Smith RA;
Neurology; 2004 Oct; 63(8):1364-70. PubMed ID: 15505150
[TBL] [Abstract][Full Text] [Related]
10. A phase I open-label study to investigate the potential drug-drug interaction between single-dose dacomitinib and steady-state paroxetine in healthy volunteers.
Ruiz-Garcia A; Giri N; LaBadie RR; Ni G; Boutros T; Richie N; Kocinsky HS; Checchio TM; Bello CL
J Clin Pharmacol; 2014 May; 54(5):555-62. PubMed ID: 24293056
[TBL] [Abstract][Full Text] [Related]
11. Evaluating the safety and efficacy of dextromethorphan/quinidine in the treatment of pseudobulbar affect.
Schoedel KA; Morrow SA; Sellers EM
Neuropsychiatr Dis Treat; 2014; 10():1161-74. PubMed ID: 25061302
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.
Walzer M; Bekersky I; Blum RA; Tolbert D
Pharmacotherapy; 2012 Apr; 32(4):340-53. PubMed ID: 22422635
[TBL] [Abstract][Full Text] [Related]
13. Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect.
Pioro EP; Brooks BR; Cummings J; Schiffer R; Thisted RA; Wynn D; Hepner A; Kaye R;
Ann Neurol; 2010 Nov; 68(5):693-702. PubMed ID: 20839238
[TBL] [Abstract][Full Text] [Related]
14. An open-label study to assess safety, tolerability, and effectiveness of dextromethorphan/quinidine for pseudobulbar affect in dementia: PRISM II results.
Doody RS; D'Amico S; Cutler AJ; Davis CS; Shin P; Ledon F; Yonan C; Siffert J
CNS Spectr; 2016 Dec; 21(6):450-459. PubMed ID: 26471212
[TBL] [Abstract][Full Text] [Related]
15. The effect of dacomitinib (PF-00299804) on CYP2D6 activity in healthy volunteers who are extensive or intermediate metabolizers.
Bello CL; LaBadie RR; Ni G; Boutros T; McCormick C; Ndongo MN
Cancer Chemother Pharmacol; 2012 Apr; 69(4):991-7. PubMed ID: 22147075
[TBL] [Abstract][Full Text] [Related]
16. Effect of metabolic blockade on the psychoactive effects of dextromethorphan.
Zawertailo LA; Tyndale RF; Busto U; Sellers EM
Hum Psychopharmacol; 2010 Jan; 25(1):71-9. PubMed ID: 20041473
[TBL] [Abstract][Full Text] [Related]
17. Dextromethorphan/quinidine for the treatment of pseudobulbar affect.
Patatanian E; Casselman J
Consult Pharm; 2014 Apr; 29(4):264-9. PubMed ID: 24704895
[TBL] [Abstract][Full Text] [Related]
18. Dextromethorphan/quinidine: in pseudobulbar affect.
Garnock-Jones KP
CNS Drugs; 2011 May; 25(5):435-45. PubMed ID: 21476614
[TBL] [Abstract][Full Text] [Related]
19. Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis.
Panitch HS; Thisted RA; Smith RA; Wynn DR; Wymer JP; Achiron A; Vollmer TL; Mandler RN; Dietrich DW; Fletcher M; Pope LE; Berg JE; Miller A;
Ann Neurol; 2006 May; 59(5):780-7. PubMed ID: 16634036
[TBL] [Abstract][Full Text] [Related]
20. Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.
Foster RH; Goa KL
CNS Drugs; 1997 Aug; 8(2):163-88. PubMed ID: 23338224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]